Table 2 Platelet characteristics in the JUMBO substudy and historic clopidogrel controls.
| Parameter | Study group | Baseline | 4 hours | 24 hours | 30 days |
|---|---|---|---|---|---|
| Conventional optical aggregometry | |||||
| ADP 5 µM (%) | CS‐747‐I (1) | 57 | 18 | 21 | 30 |
| CS‐747‐II (4) | 82.0 (11.3) | 8.5 (4.7)* | 9.8 (8.3)* | 40.0 (17.8)* | |
| CS‐747‐III (2) | 31.5 (37.5) | 7.0 (2.8)* | 11.5 (9.2)* | 19.0 (7.1)* | |
| CS‐747 (total) | 56.8 (31.9) | 9.4 (5.2)*† | 11.9 (8.1)*† | 32.6 (16.3)*† | |
| Clopidogrel (2) | 67.0 (8.5) | 40.0 (2.8)* | 66.0 (22.6) | 41.0 (14.1)* | |
| Clopidogrel (historic) | 53.1 (12.8) | 26.8 (10.8)* | 32.9 (14.5)* | 21.4 (6.0)* | |
| ADP 20 µM ** (%) | CS‐747‐I (1) | 59 | 26 | 28 | 57 |
| CS‐747‐II (4) | 67.0 (0.0) | 7.3 (7.9)* | 8.5 (12.4)* | 57.3 (16.0) | |
| CS‐747‐III (2) | 41.0 (56.6) | 14.0 (17.0)* | 21.5 (26.2)* | 29.0 (2.8)* | |
| CS‐747 (total) | 55.0 (31.2) | 11.9 (11.3)* | 15.0 (16.2)* | 49.1 (17.8) | |
| Clopidogrel (2) | 56.0 (9.9) | 47.5 (13.4) | 82.0 (21.2) | 56.0 (14.1) | |
| Collagen 4 µg/ml (%) | CS‐747‐I (1) | 51 | 13 | 18 | 30 |
| CS‐747‐II (4) | 52.5 (3.5) | 2.8 (2.9) | 5.5 (8.3) | 22.5 (30.2) | |
| CS‐747‐III (2) | 30.0 (39.6) | 4.0 (4.2)* | 13.5 (17.7)* | 19.5 (3.5)* | |
| CS‐747 (total) | 43.2 (23.3) | 4.6 (4.6)*† | 9.6 (10.7)*† | 22.7 (21.7)*† | |
| Clopidogrel (2) | 57.5 (12.0) | 25.0 (11.3)* | 60.0 (50.9) | 29.5 (23.3)* | |
| Collagen 5 µg/ml (%) | Clopidogrel (historic) | 56.8 (14.6) | 20.3 (9.9)* | 29.4 (15.8)* | 38.3 (5.2)* |
| Verify Now P2Y12 analyser | |||||
| ULTEGRA* (PAU) | CS‐747‐I (1) | 691 | 405 | 394 | 525 |
| CS‐747‐II (4) | 643 (40) | 26 (10)* | 145 (189)* | 545 (172) | |
| CS‐747‐III (2) | 425 (45) | 198 (147)* | 211 (179)* | 257 (42)* | |
| CS‐747 (total) | 565 (261)† | 129 (158)*† | 199 (177)*† | 431 (186)† | |
| Clopidogrel (2) | 360 (99) | 283 (139) | 499 (224) | 367 (249) | |
| Clopidogrel(12) (prospective) | 338 (54) | 280 (72) | 285 (69) | 168 (72)* | |
| Flow cytometry | |||||
| CD31 (PECAM‐1) (log MFI) | CS‐747‐I (1) | 68.07 | 24.89 | 26.09 | 43.21 |
| CS‐747‐II (4) | 55.5 (5.6) | 63.4 (31.2) | 63.5 (32.5) | 38.3 (31.2)* | |
| CS‐747‐III (2) | 85.3 (23.9) | 44.5 (29.2)* | 44.8 (21.8)* | 18.1 (0.7)* | |
| CS‐747 (total) | 69.9 (19.3) | 52.5 (29.3)† | 52.8 (28.7)† | 33.2 (24.4)*† | |
| Clopidogrel (2) | 68.5 (8.8) | 42.8 (1.3)* | 50.5 (15.6)* | 68.8 (35.2) | |
| Clopidogrel (historic) | 62.9 (12.2) | 41.6 (17.3)* | 38.0 (18.9)* | 58.6 (8.4) | |
| CD41 (GP‐IIb antigen) (log MFI) | CS‐747‐I (1) | 344 | 183 | 135 | 261 |
| CS‐747‐II (4) | 266 (25) | 194 (61) | 179 (50)* | 283 (22) | |
| CS‐747‐III (2) | 306 (260) | 203 (137)* | 198 (97)* | 309 (31) | |
| CS‐747 (total) | 258 (83) | 195 (71)† | 178 (57)*† | 330 (99)† | |
| Clopidogrel (2) | 350 (34) | 325 (48) | 416 (28) | 409 (83) | |
| Clopidogrel (historic) | 357 (51) | 325 (49) | 347 (58) | 251 (42)* | |
| PAC‐1 (GPIIb/IIIa activity) (log MFI) | CS‐747‐I (1) | 8.81 | 4.84 | 4.12 | 5.02 |
| CS‐747‐II (4) | 11.6 (3.8) | 5.2 (2.4)* | 4.9 (2.1)* | 7.1 (3.0)* | |
| CS‐747‐III (2) | 7.2 (5.6) | 5.9 (1.9) | 4.5 (1.0)* | 6.4 (0.2) | |
| CS‐747 (total) | 9.3 (4.1) | 5.3 (1.9)*† | 4.7 (1.6)*† | 6.6 (2.3)*† | |
| Clopidogrel (2) | 8.9 (0.6) | 5.6 (0.7)* | 8.2 (0.8) | 11.2 (1.0) | |
| Clopidogrel (historic) | 10.0 (2.1) | 6.7 (1.5)* | 9.6 (2.5) | 9.3 (2.3) | |
| CD42 (GP‐Ib) (log MFI) | CS‐747‐I (1) | 124.5 | 90.8 | 131.8 | 102.6 |
| CS‐747‐II (4) | 136.4 (29.8) | 161.9 (33.2) | 162.0 (47.9) | 146.6 (56.0) | |
| CS‐747‐III (2) | 166.2 (51.8) | 116.2 (6.9) | 149.3 (41.9) | 96.1 (13.7)* | |
| CS‐747 (total) | 145.9 (35.5) | 138.7 (38.3) | 154.0 (39.6)† | 125.9 (47.7)† | |
| Clopidogrel (2) | 120.3 (4.4) | 143.2 (20.6) | 133.3 (23.3) | 163.2 (48.7) | |
| Clopidogrel (historic) | 135.2 (35.1) | 134.2 (37.3) | 129.8 (37.6) | 168.0 (48.0) | |
| CD51/61 (vitronectin) (log MFI) | CS‐747‐I (1) | 7.74 | 8.91 | 8.32 | 10.18 |
| CS‐747‐II (4) | 10.1 (0.8) | 9.1 (1.6) | 8.8 (1.8) | 8.9 (2.5) | |
| CS‐747‐III (2) | 6.4 (0.2) | 5.8 (0.2) | 6.6 (0.4) | 7.0 (0.9) | |
| CS‐747 (total) | 8.2 (1.9) | 8.1 (2.0)† | 8.1 (1.7) | 8.5 (2.2) | |
| Clopidogrel (2) | 8.1 (0.9) | 7.6 (0.7) | 7.6 (1.8) | 9.6 (0.9) | |
| Clopidogrel (historic) | 7.9 (1.7) | 6.9 (1.6) | 7.4 (1.9) | 9.2 (2.0) | |
| CD62p (P‐selectin) (%+) | CS‐747‐I (1) | 6.06 | 6.36 | 5.99 | 7.68 |
| CS‐747‐II (4) | 10.4 (0.5) | 8.9 (1.2) | 8.4 (1.5) | 6.0 (3.0)* | |
| CS‐747‐III (2) | 13.4 (5.4) | 10.2 (7.1) | 7.9 (0.5)* | 4.9 (0.6)* | |
| CS‐747 | 10.8 (4.1) | 8.9 (3.3) | 7.9 (1.4)*† | 5.9 (2.3)*† | |
| Clopidogrel (2) | 7.8 (1.6) | 6.7 (1.2) | 8.4 (0.0) | 10.5 (1.0) | |
| Clopidogrel (historic) | 10.4 (3.4) | 10.0 (3.5) | 9.8 (3.6) | 9.6 (1.4) | |
| CD63 (LAMP‐3) (log MFI) | CS‐747‐I (1) | 7.41 | 6.23 | 8.69 | 7.34 |
| CS‐747‐II (4) | 7.6 (0.7) | 6.4 (0.8) | 6.1 (0.7) | 7.2 (1.6) | |
| CS‐747‐III (2) | 4.4 (1.1) | 5.7 (2.1) | 4.8 (0.7) | 3.8 (0.4) | |
| CS‐747 (total) | 6.3 (1.8) | 6.2 (1.1) | 6.1 (1.4) | 6.3 (2.0) | |
| Clopidogrel (2) | 4.3 (1.6) | 4.5 (1.3) | 4.5 (2.1) | 6.0 (2.7) | |
| Clopidogrel (historic) | 6.5 (1.5) | 6.1 (1.7) | 6.6 (1.5) | 6.5 (2.5) | |
| CD107a (LAMP‐1) (log MFI) | CS‐747‐I (1) | 3.41 | 2.27 | 2.49 | 3.04 |
| CS‐747‐II (4) | 6.1 (0.8) | 5.4 (2.4) | 4.4 (2.2)* | 5.6 (3.0) | |
| CS‐747‐III (2) | 4.2 (2.0) | 1.5 (0.1)* | 2.2 (1.0)* | 3.9 (2.0) | |
| CS‐747 (total) | 4.8 (1.6) | 3.8 (2.6) | 3.5 (1.9) | 4.7 (2.5) | |
| Clopidogrel (2) | 4.3 (1.6) | 4.6 (1.2) | 4.5 (1.9) | 6.0 (1.6) | |
| Clopidogrel (historic) | 4.8 (1.6) | 2.9 (1.1)* | 2.7 (1.2)* | 5.8 (2.1) | |
| CD151+CD14 (log MFI) | CS‐747‐I (1) | 83.52 | 49.85 | 53.53 | 64.32 |
| CS‐747‐II (4) | 63.5 (1.6) | 64.4 (25.4) | 64.0 (40.7) | 68.2 (28.0) | |
| CS‐747‐III (2) | 77.3 (12.7) | 56.5 (0.3)* | 64.7 (6.5) | 51.8 (21.5)* | |
| CS‐747 (total) | 73.0 (11.1) | 60.1 (18.9) | 62.7 (29.2) | 62.9 (23.0) | |
| Clopidogrel (2) | 54.0 (44.2) | 49.6 (30.6) | 59.4 (34.8) | 55.1 (1.1) | |
| Clopidogrel (historic) | 67.1 (14.5) | 62.6 (14.4) | 69.5 (22.4) | 66.0 (9.5) | |
| CD40‐ligand (log MFI) | CS‐747‐I (1) | 7.91 | 5.76 | 2.93 | 3.56 |
| CS‐747‐II (4) | 6.7 (1.0) | 5.3 (1.1) | 5.2 (0.4) | 4.6 (1.7)* | |
| CS‐747‐III (2) | 6.7 (0.6) | 3.6 (1.7)* | 4.1 (1.2)* | 3.5 (0.1)* | |
| CS‐747 (total) | 6.9 (0.8) | 4.8 (1.4)* | 4.6 (1.1)* | 4.1 (1.3)*† | |
| Clopidogrel (2) | 4.5 (0.2) | 6.2 (2.2) | 4.8 (0.6) | 6.9 (0.6) | |
| Clopidogrel (historic) | 5.5 (1.3) | 4.1 (1.3)* | 4.2 (1.3)* | 6.5 (1.6) | |
| CD165 (log MFI) | CS‐747‐I (1) | 27.4 | 26.3 | 25.35 | 7.28 |
| CS‐747‐II (4) | 21.7 (0.1) | 13.9 (3.3)* | 12.2 (3.3)* | 17.4 (6.9) | |
| CS‐747‐III (2) | 26.4 (1.1) | 21.1 (1.8) | 18.3 (2.9) | 11.8 (5.5)* | |
| CS‐747 (total) | 24.7 (2.8) | 17.8 (5.6)* | 15.8 (5.7)* | 14.3 (6.7)*† | |
| Clopidogrel (2) | 17.0 (7.7) | 13.7 (2.1) | 15.0 (1.7) | 19.5 (11.5) | |
| Clopidogrel (historic) | 23.9 (5.2) | 17.8 (5.8) | 18.3 (4.2) | 19.7 (3.0) | |
| PAR‐1 activated WEDE15 (log MFI) | CS‐747‐I (1) | 34.6 | 16.64 | 25.4 | 25.4 |
| CS‐747‐II (4) | 8.2 (2.0) | 16.1 (8.4)* | 15.8 (9.6)* | 20.3 (14.0)* | |
| CS‐747‐III (2) | 36.0 (19.1) | 19.0 (3.5)* | 24.4 (2.9)* | 16.5 (2.8)* | |
| CS‐747 (total) | 37.0 (9.8) | 17.0 (6.2)*† | 19.6 (8.4)*† | 18.8 (10.7)* | |
| Clopidogrel (2) | 32.8 (5.0) | 21.3 (1.4)* | 28.9 (6.6) | 35.1 (7.1) | |
| Clopidogrel (historic) | 30.2 (10.9) | 20.9 (9.3) | 25.7 (9.6) | 16.5 (3.2)* | |
| PAR‐1 intact SPAN12 (log MFI) | CS‐747‐I (1) | 9.8 | 16.4 | 18.87 | 27.5 |
| CS‐747‐II (4) | 11.5 (2.8) | 18.3 (7.6) | 12.1 (3.0) | 23.2 (12.2) | |
| CS‐747‐III (2) | 22.4 (7.9) | 12.6 (4.2)* | 12.1 (4.0)* | 15.7 (2.1)* | |
| CS‐747 (total) | 19.5 (5.4) | 13.3 (2.5)† | 12.0 (2.7)*† | 9.6 (8.1)* | |
| Clopidogrel (2) | 20.0 (2.1) | 13.3 (2.9)* | 19.5 (0.0) | 23.2 (5.2) | |
| Clopidogrel (historic) | 18.0 (4.8) | 16.2 (5.0) | 17.1 (5.3) | 6.2 (0.9)* | |
| Thrombospondin (log MFI) | CS‐747‐I (1) | 7.45 | 6.4 | 5.3 | 2.88 |
| CS‐747‐II (4) | 8.7 (3.0) | 6.4 (1.6)* | 6.7 (1.3)* | 5.6 (2.6)* | |
| CS‐747‐III (2) | 5.7 (0.7) | 6.3 (0.1) | 7.5 (3.1) | 4.0 (0.2) | |
| CS‐747 (total) | 7.3 (2.2) | 6.4 (1.1) | 6.7 (1.7) | 4.8 (2.1)*† | |
| Clopidogrel (2) | 4.5 (0.5) | 5.0 (0.5) | 7.5 (1.9)* | 9.2 (2.7)* | |
| Clopidogrel (historic) | 7.1 (2.0) | 6.7 (2.0) | 7.8 (2.8) | 8.1 (1.3) | |
*p Value compared with own baseline; p<0.05; **no historic data available; †p value CS‐747 total compared with. clopidogrel historic <0.05. PAU, platelet activation units; MFI, mean fluorescence intensity; %+, percentage of positive cells.